医药行业周报：诺华以近30亿美元获得亨廷顿病小分子疗法

Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical industry, expecting an overall return exceeding 5% above the CSI 300 index in the next six months [5]. Core Insights - The pharmaceutical sector experienced a slight decline of -0.30% on December 3, 2024, underperforming the CSI 300 index by 0.41 percentage points, ranking 23rd among 31 sub-industries [1]. - Notable sub-industry performances included medical research outsourcing (+0.56%), vaccines (+0.40%), and medical consumables (+0.10%), while offline pharmacies (+0.53%), medical devices (+0.79%), and hospitals (+0.85%) lagged behind [1]. - PTC Therapeutics announced a global licensing and collaboration agreement with Novartis for the Huntington's disease project PTC518, which includes a $1 billion upfront payment and potential milestone payments up to $1.9 billion [1]. - The report highlights the successful Phase II clinical trial results of D-2570, a novel oral selective inhibitor targeting TYK2 for psoriasis, showing a PASI 75 response rate of 85.0%-90.0% after 12 weeks, significantly higher than the placebo group [1]. Summary by Sections Market Performance - The pharmaceutical sector's performance on December 3, 2024, was -0.30%, underperforming the CSI 300 index by 0.41 percentage points [1]. - The top-performing sub-industries included medical research outsourcing, vaccines, and medical consumables, while offline pharmacies, medical devices, and hospitals showed weaker performance [1]. Industry News - PTC Therapeutics signed a global licensing agreement with Novartis for PTC518, a small molecule drug for Huntington's disease, with significant financial implications [1]. - The report also covers the positive clinical trial results for D-2570, indicating strong efficacy in treating psoriasis [1].